Disc Medicine, Inc. (NASDAQ:IRON) Receives $104.80 Average Target Price from Analysts

Shares of Disc Medicine, Inc. (NASDAQ:IRON) have earned a consensus rating of “Moderate Buy” from the twelve analysts that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and ten have given a buy recommendation to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $104.80.

IRON has been the subject of several research reports. Wedbush dropped their price target on shares of Disc Medicine from $110.00 to $88.00 and set an “outperform” rating for the company in a research note on Tuesday, February 17th. Morgan Stanley set a $75.00 price objective on Disc Medicine in a research note on Tuesday, February 17th. Stifel Nicolaus decreased their target price on Disc Medicine from $125.00 to $110.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. BMO Capital Markets cut their price target on Disc Medicine from $120.00 to $100.00 and set an “outperform” rating on the stock in a report on Tuesday, February 17th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Disc Medicine in a research report on Friday, December 19th.

Insider Activity

In related news, insider Rahul Khara sold 2,853 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $62.86, for a total value of $179,339.58. Following the sale, the insider owned 52,173 shares of the company’s stock, valued at $3,279,594.78. This trade represents a 5.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Pamela Stephenson sold 5,531 shares of Disc Medicine stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $62.86, for a total transaction of $347,678.66. Following the completion of the transaction, the insider owned 80,998 shares of the company’s stock, valued at $5,091,534.28. This represents a 6.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 292,492 shares of company stock valued at $25,423,925. 3.64% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Disc Medicine

Institutional investors have recently modified their holdings of the company. TimesSquare Capital Management LLC purchased a new position in shares of Disc Medicine in the 3rd quarter valued at $12,038,000. Y Intercept Hong Kong Ltd lifted its position in Disc Medicine by 361.4% in the third quarter. Y Intercept Hong Kong Ltd now owns 43,287 shares of the company’s stock valued at $2,860,000 after acquiring an additional 33,905 shares during the last quarter. Atle Fund Management AB boosted its stake in Disc Medicine by 85.3% in the third quarter. Atle Fund Management AB now owns 45,690 shares of the company’s stock valued at $3,019,000 after acquiring an additional 21,038 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Disc Medicine by 11.1% in the second quarter. JPMorgan Chase & Co. now owns 843,616 shares of the company’s stock valued at $44,678,000 after acquiring an additional 84,278 shares in the last quarter. Finally, Assenagon Asset Management S.A. purchased a new position in shares of Disc Medicine during the third quarter worth about $689,000. 83.70% of the stock is owned by hedge funds and other institutional investors.

Disc Medicine Stock Up 5.0%

Shares of IRON opened at $64.23 on Thursday. The company’s 50-day simple moving average is $72.41 and its 200-day simple moving average is $75.77. The company has a debt-to-equity ratio of 0.04, a quick ratio of 21.94 and a current ratio of 21.94. Disc Medicine has a 1 year low of $30.82 and a 1 year high of $99.50. The stock has a market capitalization of $2.42 billion, a PE ratio of -10.72 and a beta of 0.87.

Disc Medicine (NASDAQ:IRON) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($1.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.69) by $0.07. The business had revenue of ($19.88) million during the quarter, compared to analyst estimates of $0.15 million. Analysts forecast that Disc Medicine will post -4.07 earnings per share for the current fiscal year.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.